4541.T
現在値
389.00JPY変化
54.00(+16.12%)出来高
9,123,800本日のレンジ
-
400.0052週レンジ
-
979.00∙ 約20分前の相場を表示しています。
July 24 (Reuters) - EMA::EMA - REVIEWING RESULTS FROM RECOVERY STUDY ARM THAT INVOLVED THE USE OF DEXAMETHASONE IN THE TREATMENT OF PATIENTS WITH COVID-19 ADMITTED TO HOSPITAL.EMA - RECOVERY STUDY RECORDED DEATHS DURING 28 DAYS AFTER STARTING DEXAMETHASONE TREATMENT.EMA - PRELIMINARY RESULTS INDICATE DEXAMETHASONE REDUCED MORTALITY BY ABOUT 35% IN PATIENTS ON INVASIVE MECHANICAL VENTILATION VERSUS WITH USUAL CARE.EMA - PRELIMINARY RESULTS INDICATE DEXAMETHASONE REDUCED MORTALITY BY ABOUT 20% IN PATIENTS RECEIVING OXYGEN WITHOUT INVASIVE VENTILATION.EMA - PRELIMINARY RESULTS INDICATE DEXAMETHASONE DID NOT REDUCE DEATH IN PATIENTS WHO WERE NOT RECEIVING OXYGEN THERAPY.
Sept 5 (Reuters) - Sagent Pharmaceuticals::SAGENT PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF OMEGA MANUFACTURING SITE.SAGENT PHARMACEUTICALS - OMEGA LABORATORIES LTD HAS BEEN FOUND ACCEPTABLE FOR MANUFACTURING FDA-APPROVED PRODUCTS.
Nov 12(Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says 20,000 units of its ninth series options were exercised to 2 million shares of its common stock on Nov. 12.
Aug 29(Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says 16,500 units of its ninth series options were exercised to 1.65 million shares of its common stock on Aug. 15 and Aug. 29.
June 18 (Reuters) - Lupin Ltd <LUPN.NS>::SAYS CO, NICHI-IKO ANNOUNCE PARTNERSHIP FOR COMMERCIALIZATION OF BIOSIMILAR ETANERCEPT IN JAPAN.SAYS PRODUCT WILL BE LAUNCHED BY NICHI-IKO AFTER RECEIVING APPROVAL FROM PHARMACEUTICALS AND MEDICAL DEVICES AGENCY.
April 9 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japanese Generally Accepted Accounting Principles.IFRS effective from the annual report for fiscal year ended March 2018.
March 28 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it forms business and capital alliance with Eisai Co Ltd <<<4523.T>>>.Says two entities will mainly cooperate on generic drug business model reform, ecosystem construction and API application .Says it will acquire 100 percent stake in ELMED EISAI Co Ltd from Eisai Co Ltd, for 17.12 billion yen in total.Says it plans to complete stake acquisition on April 1, 2019 .
Nov 28 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it will start sales of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko" on Nov. 29.
Oct 2(Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it merged with a wholly owned unit, on Oct. 1.
Sept 27 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:* Says it received marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" from the Ministry of Labour, Health, and Welfare on Sept. 27 .* Says its unit, Yakuhan Pharmaceutical Co Ltd, received manufacturing and marketing approval for Infliximab BS for I.V. infusion 100 mg "AYUMI" .
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。